<DOC>
	<DOCNO>NCT03015402</DOCNO>
	<brief_summary>The main objective study determine clinical efficacy oral inorganic nitrite verse placebo therapeutic response regard exercise tolerance patient pulmonary hypertension heart failure preserve ejection fraction ( PH-HFpEF ) .</brief_summary>
	<brief_title>Oral Nitrite Patients With Pulmonary Hypertension Heart Failure With Preserved Ejection Fraction</brief_title>
	<detailed_description>This single-center , 26-week double-blind , randomize placebo-controlled cross-over trial oral nitrite exercise capacity hemodynamic measurement subject PH-HFpEF .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Age 18 year old Screening blood pressure ( BP ) either systolic diastolic state level baseline BP ≤ 170/95 PHHFpEF confirm diagnosis RHC : Mean Pulmonary Arterial Pressure ( mPAP ) ≥ 25 mmHg AND Pulmonary capillary wedge pressure ( PWCP ) ≥ 15 mmHg AND Transpulmonary Gradient ( TPG ) ≥ 12 mmHg Age le 18 year ; SBP &gt; 170 &lt; 110 mmHg DBP &gt; 95 &lt; 60 mmHg Hemoglobin A1C &gt; 10 Positive urine pregnancy test breastfeeding ; Ejection Fraction ( EF ) &lt; 40 % ; Dementia Endstage malignancy Major cardiovascular event procedure within 6 week prior enrollment Severe valvular disease Known chronic psychiatric medical condition may increase risk associate study participation judgment investigator , would make subject inappropriate entry study ; Smoker Hemoglobin &lt; 9 g/dL Serum creatinine &gt; 3.0 mg/dL Receipt investigational product device , participation drug research study within period 15 day ; RHC &lt; 2 week study screen RHC unless clinically indicate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>